Susana Pereira1,2, Filipa Fontes2,3, Teresa Sonin1, Teresa Dias1, Maria Fragoso1, José M Castro-Lopes4,5, Nuno Lunet6,7. 1. Portuguese Institute of Oncology of Porto, Rua Dr. António Bernardino de Almeida, 4200-075, Porto, Portugal. 2. EPIUnit-Institute of Public Health, University of Porto (ISPUP), Rua das Taipas, n 135, 4050-600, Porto, Portugal. 3. Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. 4. Department of Experimental Biology, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. 5. Institute for Molecular and Cell Biology (IBMC), University of Porto, Rua do Campo Alegre, n 823, 4150-180, Porto, Portugal. 6. EPIUnit-Institute of Public Health, University of Porto (ISPUP), Rua das Taipas, n 135, 4050-600, Porto, Portugal. nlunet@med.up.pt. 7. Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. nlunet@med.up.pt.
Abstract
PURPOSE: The purposes of this study were to estimate the incidence of chemotherapy-induced peripheral neuropathy (CIPN) and to identify its main determinants and impact in patient-reported outcomes. METHODS: We performed a prospective cohort study including 296 patients with incident breast cancer submitted to chemotherapy, followed for 1 year. Patients with incident CIPN were reevaluated 6 months after this diagnosis. Relative risks (RR) with 95 % confidence intervals (95 % CI) were computed to quantify the relation between different clinical characteristics and the occurrence of CIPN, using Poisson regression. The variation of patient-reported outcomes between baseline and 1-year follow-up assessments was compared between patients with and without CIPN. RESULTS: The cumulative incidence of CIPN in the first year after diagnosis was 28.7 % (95 % CI 23.8-34.1), and more than 80 % of the patients were still symptomatic after 6 months. Among the latter, there was a significant decrease in the median total neuropathy score, clinical version (7 versus 4) between the two periods. In multivariable analysis, the risk of CIPN was higher for treatment with docetaxel (cumulative doses ≤300 mg/m(2), RR = 6.96, 95 % CI 2.53-19.10; >300 mg/m(2), RR = 13.32; 95 % CI 4.11-43.14). Alcohol consumption and diabetes were not significantly associated with CIPN. There were no significant differences in the variation of patient-reported outcomes between the baseline and 1-year follow-up evaluations. CONCLUSIONS: CIPN was frequent in this contemporary cohort of early-stage breast cancer patients and was strongly associated with docetaxel-based regimens. Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes.
PURPOSE: The purposes of this study were to estimate the incidence of chemotherapy-induced peripheral neuropathy (CIPN) and to identify its main determinants and impact in patient-reported outcomes. METHODS: We performed a prospective cohort study including 296 patients with incident breast cancer submitted to chemotherapy, followed for 1 year. Patients with incident CIPN were reevaluated 6 months after this diagnosis. Relative risks (RR) with 95 % confidence intervals (95 % CI) were computed to quantify the relation between different clinical characteristics and the occurrence of CIPN, using Poisson regression. The variation of patient-reported outcomes between baseline and 1-year follow-up assessments was compared between patients with and without CIPN. RESULTS: The cumulative incidence of CIPN in the first year after diagnosis was 28.7 % (95 % CI 23.8-34.1), and more than 80 % of the patients were still symptomatic after 6 months. Among the latter, there was a significant decrease in the median total neuropathy score, clinical version (7 versus 4) between the two periods. In multivariable analysis, the risk of CIPN was higher for treatment with docetaxel (cumulative doses ≤300 mg/m(2), RR = 6.96, 95 % CI 2.53-19.10; >300 mg/m(2), RR = 13.32; 95 % CI 4.11-43.14). Alcohol consumption and diabetes were not significantly associated with CIPN. There were no significant differences in the variation of patient-reported outcomes between the baseline and 1-year follow-up evaluations. CONCLUSIONS: CIPN was frequent in this contemporary cohort of early-stage breast cancerpatients and was strongly associated with docetaxel-based regimens. Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes.
Entities:
Keywords:
Breast neoplasm; Peripheral nerve injuries; Quality of life
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Elisabeth G Vichaya; Xin Shelley Wang; Jessica A Boyette-Davis; Tito R Mendoza; Zijing He; Sheeba K Thomas; Nina Shah; Loretta A Williams; Charles S Cleeland; Patrick M Dougherty Journal: Cancer Chemother Pharmacol Date: 2013-03-31 Impact factor: 3.333
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: M Eileen Dolan; Omar El Charif; Heather E Wheeler; Eric R Gamazon; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Jeri Kim; Sophie D Fossa; Daniel L Hertz; Taisei Mushiroda; Michiaki Kubo; Lawrence H Einhorn; Nancy J Cox; Lois B Travis Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: Dawn L Hershman; Joseph M Unger; Katherine D Crew; Cathee Till; Heather Greenlee; Lori M Minasian; Carol M Moinpour; Danika L Lew; Louis Fehrenbacher; James L Wade; Siu-Fun Wong; Michael J Fisch; N Lynn Henry; Kathy S Albain Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Dawn L Hershman; Cathee Till; Jason D Wright; Danielle Awad; Scott D Ramsey; William E Barlow; Lori M Minasian; Joseph Unger Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Kristine Bennedsgaard; Lise Ventzel; Andreas C Themistocleous; David L Bennett; Anders B Jensen; Anni R Jensen; Niels T Andersen; Troels S Jensen; Hatice Tankisi; Nanna B Finnerup Journal: Cancer Med Date: 2020-05-29 Impact factor: 4.452